𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pamidronic acid: approval in Japan for osteolytic bone metastasis

Book ID
120854360
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2005
Weight
150 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pamidronate for pain control in patients
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
✍ B. ThΓΌrlimann; R. Morant; W. F. Jungi; A. Radziwill πŸ“‚ Article πŸ“… 1994 πŸ› Springer-Verlag 🌐 English βš– 495 KB

In a prospective dose-escalation study tolerability and effectiveness of repeated infusions with intravenous pamidronate were investigated. A total of 80 patients with proven malignancy and pain due to osteolytic bone disease were enrolled. Doses of 30 mg, 45 mg, 60 mg and 90 mg pamidronate, given e

Zoledronic acid is superior to pamidrona
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who